Cannabinoids

764 Subject Index

paraventricular nucleus 313
ventralmedialhypothalamicnu-
cleus 313
ventromedial nucleus 559
hypothermia seebodytemperature

ibuprofen 194

IFN-α/β 397

IFN-γ 398, 401

IL-1 392

IL-1 converting enzyme 392
IL-2 392, 395, 396
IL-2 receptor 392, 396
IL-4 398
IL-6 398, 400, 403
IL-8 397, 398
IL-10 397, 398
IL-12 397, 401

IL1-α 401

ileum 345, 347
imidazoline 31
immunohistochemistry 575, 583,
585
immunological tolerance 390
implantation 564
indomethacin 194
inducible NO synthase 606
inflammation 574, 587, 590
inhibitory neurotransmission 341
central nervous system 337
insect 291
insomnia 738
interleukin(IL),IL-3,IL-4,IL-10 566
interpretation 672
intracellular free Ca2+ 3, 4, 11
inverseagonism/agonist 22–24,353,
702
invertebrate 285–287,289,291,292,
294
invertebrates 290
inwardly rectifying potassium chan-
nels 60, 329
iodoantipyrine 429
IP 3 58
ischemic preconditioning 617

JNK1 63

JNK2 63

Jun N-terminal Kinases 63

JWH-015 15, 19, 35, 36, 613

JWH-133 9, 13, 20

Kaposi’s sarcoma 404, 405

kinetic modeling 429

knockout mice

seecannabinoid receptor

krox-24 62

L-Dopa-induced dyskinesia 728

L. pneumophila 400, 401

lamina terminalis 556

lamprey 290

leech 287, 292

legal controls 721

Legionella pneumophila 399

leptin 559, 560

human T cells 560

levonantradol (L-nantradol) 4, 13,

68, 235, 729

Leydig cells 564

ligand–ligand studies

aminoalkylindoles 266

classical/non-classicalCBs 254

CoMFA 267

endocannabinoids 262

SR141716A 270

ligand–receptor modeling

endocannabinoid 263

ligand–receptor models

SR141716A 272

ligand–receptor studies

aminoalkylindole 269

classical/non-classicalCB 257

ligand-gated ion channels 330

lipophilic 386

lipopolysaccharide (LPS) 616

Listeria monocytogenes 400

liver cirrhosis 600, 615, 616, 618

locomotion 120

long-term depression (LTD) 465

long-term potentiation (LTP) 460

lophotrochozoa 285